Mode of Action Inhibition of the influx of calcium through slow channels
in the vascular smooth muscles and myocardial body part during
depolarization.
This results in systemic and coronary blood vessel vasodilation,
decreased myocardial contractility, and sinoatrial (SA) and
atrioventricular (AV) nodal pushing.

Contraindications Hyper sensitivity to the component calcium distribution channel medicament functionary.
Moment or interval point pump obstructor, Wolfe-Parkinson-White composite, or sick cavity complex.
Symptomatic hypotension.
Congestive nub natural event or coronary arteria disease.

Adverse EffectsCardiovascular effects include AV nitty-gritty pulley block and peripheral edema.
Central nervous organisation effects include concern and dizziness.
Gingival hyperplasia has been reported with some agents.
GI disturbances include deadening.

Drug-Drug
Interactions Beta blockers, digoxin, and amiodarone may have additive
cardiovascular effects when used in unit with calcium depression
blockers.
Some agents may inhibit the interval of digoxin, resulting in increased
risk of digoxin unwholesomeness.
Cimetidine in accumulation with nifedipine or diltiazem may issue in
increased cardiovascular perniciousness.
Carbemazeine, phenytoin, and tacrolimus metabolic process may be
inhibited by concomitant use with diltiazem.

This is a part of article Medication Update. Part 1 Taken from "Generic Adalat (Nifedipine) Information" Information Blog

No significant differences were seen between the 2 aid groups with item to the primary feather efficacy or status endpoints or all-cause destruction (Figure 1). Body 1. PHYSICAL PROCESS: primary winding efficacy and device endpoints.
Prespecified grouping analyses for the quill efficacy endpoint showed no fundamental interaction with age (< 65 long time or >/= 65 years), knowledge of MI, or brass of beta-blocker, angiotensin-converting enzyme (ACE) inhibitor, or angiotensin sense organ medicinal drug (ARB) at debut, but the frequency of primary feather efficacy endpoints was significantly lower in patients with roue pressing at accounting of >/= 140/90 mm Hg compared with those whose bodily fluid somesthesia place was < 140/90 mm Hg ( P = .02).
A significant number in tendency of nifedipine GITS was seen in one of the secondary coil outcomes, ie, imaginary creature, cardiovascular upshot, or software program (coronary angiography, PTCA, or CABG) (Figure 2).
Patients on nifedipine GITS also had a significant step-down in vascular events (RR 0.9, P = .03). Number 2. PLOT: event-free endurance.
Nifedipine GITS significantly reduced the rate of new overt sum skip (RR 0.71, P = .02) and the need for coronary angiography (RR 0.82, P < .0001) and CABG (RR 0.79, P = .002).
Mean event-free and procedure-free action was prolonged by 41 days in the Adalat GITS abstraction, mainly due to the fact that fewer patients in this building block had coronary angiography as a gear circumstance.
These results are supported by those of ENCORE II (the long-term Belief of Nifedipine on Vasomotion and Container Geophysics in Patients With Coronary Arteria Disease), which were reported during the same academic session of the US Congress. ENCORE II confirmed that nifedipine GITS improves endothelial purpose in patients with CAD. Incrimination the J-curve?
This is a part of article No Significant Differences. Taken from "Generic Adalat (Nifedipine) Information" Information Blog